ABSTRACT Unprecedented advances in the treatment of cancer have occurred through the use of immunotherapy, with several agents currently approved by the Food and Drug Administration (FDA) for the treatment of widespread metastatic disease across cancer types. Immune checkpoint blockade represents a particularly promising class of agents that block inhibitory molecules on the surface of T cells, resulting in their activation and propagation of an immune response. Treatment with these agents may re-invigorate anti-tumor immunity, resulting in therapeutic responses, and use of these agents currently is being studied in the adjuvant setting. Additionally, a strong rationale exists for their use in the neoadjuvant setting for high-risk resectable disease (e.g., regional nodal disease in the case of melanoma). This rationale is based on the relatively high risk of relapse for these patients, as well as on scientific evidence suggesting that long-term immunologic memory and tumor control may be superior in the setting of treatment for an intact tumor (i.e., neoadjuvant therapy) as opposed to treatment in the setting of micrometastatic disease (e.g., adjuvant treatment). The potential advantages of this approach and the current landscape for neoadjuvant immune checkpoint blockade is discussed in this report, as well as caveats that should be considered by clinicians contemplating this strategy.
Cancer care has been revolutionized through the use of immunotherapy. The generation of an effective immune response against cancer is dependent on recognition of tumor antigens on a cancer cell by a cytotoxic T cell. This interaction occurs via the T cell receptor and tumor antigen presented in the context of the major histocompatibility complex (MHC), and also is dependent on a secondary immune-stimulatory signal provided by an antigen-presenting cell (Fig. 1) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] However, immune ''checkpoints'' that normally serve to downregulate an effective immune response may be upregulated in pathogenic conditions such as cancer. Therapeutic targeting of these immune checkpoints in patients with cancer has demonstrated significant success during the past decade.
Immune Checkpoint Blockade in the Setting of Advanced/Metastatic Disease
The first immune checkpoint inhibitor to be studied in clinical trials involved monoclonal blocking antibodies targeting the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on the surface of T cells (Fig. 1) . [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Expressed on activated T lymphocytes, CTLA-4 functions physiologically to downregulate an effective immune response by competing with the immunostimulatory molecule CD28 for its ligand (CD80/86) on antigen-presenting cells (APCs) -typically in lymphoid tissues. Thus, by blocking the interaction of this inhibitory molecule, T lymphocytes in the peripheral compartment may be stimulated to help mediate an anti-tumor immune response. This was first studied in patients with metastatic melanoma and reported by Hodi et al. 15 in 2010. These data demonstrated that treatment with ipilimumab, an anti-CTLA-4 antibody, was associated with durable responses in 15-20% of treated patients, substantiating the Food and Drug Administration (FDA) approval of this agent in 2011. However the clinical efficacy of these agents as monotherapy was limited for other cancer types such as non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), and small cell lung carcinoma in multiple phases I/II studies. 16 Nonetheless, additional agents targeting this axis, such as tremelimumab, are being tested alone or in combination with other strategies across multiple cancer types. 16 Another immune checkpoint that has been successfully targeted in the treatment of cancer is programmed death receptor-1 (PD-1). [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] A checkpoint receptor induced by pro-inflammatory cytokines, PD-1 binds PD-L1, its ligand expressed by a large variety of lymphoid and non-lymphoid cells and organs. Although CTLA-4 and PD-1 prevent excessive T cell responses, with CTLA-4 restricting the priming of CD4? T cells in lymphatic tissues and PD-1 restricting the action of CD8? cytotoxic T cells in the periphery in their normal functions, tumors have developed various mechanisms to evade the anti-tumor immune responses of T cells, including exploitation of the inhibitory PD-1/PD-L1 axis through PD-L1 expression to inactivate effector T cells and induce immune tolerance.
Since elucidation of the way T cell immune responses are controlled through these ''on-and-off switches,'' unprecedented strides have been made in the treatment of advanced and metastatic solid malignancies using immune checkpoint inhibitors, with numerous FDA approvals (Fig. 2) . With the successful use of these agents in the setting of stage 4 cancer treatment, these treatment methods currently are being studied in the adjuvant setting. The first of the immune checkpoint inhibitors to be tested in the adjuvant setting was ipilimumab, which was investigated in a double-blind, phase 3 trial (EORTC 18071). In this trial, 951 patients with stage 3 cutaneous melanoma (excluding lymph node metastasis B 1 mm or in-transit metastasis) who had not received previous systemic therapy for melanoma and after adequate resection of lymph nodes, were assigned to ipilimumab versus placebo. 36 The patients with completely resected high-risk stage 3 melanoma who had received adjuvant ipilimumab experienced significantly improved recurrence-free survival (RFS; median RFS, 26.1 vs. 17.1 months; p = 0.0013) during a median follow-up period of 2.74 years.
Based on these data, ipilimumab was approved for use in the adjuvant setting to treat melanoma involving regional lymph nodes ([ 1 mm involvement) after complete resection including lymphadenectomy (at 10 mg/kg every 3 weeks for 4 doses followed by 10 mg/kg every 12 weeks for up to 3 years).
The role of anti-PD-1 therapy in the adjuvant setting also is being investigated. Single-agent nivolumab was compared with ipilimumab in the adjuvant setting among patients who underwent complete resection of stage 3B/C or 4 melanoma in CheckMate-238 (NCT02388906). 37 The patient who received nivolumab had improved RFS (70. 5 45 .9%), and higher rates of completing 1 year of adjuvant therapy (60.8 vs. 26.9 %). Two trials, KEY-NOTE-054 (NCT02362594) and U.S. Intergroup Trial S1404, compared adjuvant pembrolizumab with placebo in the former trial or with standard adjuvant therapy using either highdose interferon (IFN) or high-dose ipilimumab in the latter.
RATIONALE FOR NEOADJUVANT IMMUNE CHECKPOINT BLOCKADE
The rapid progress made in cancer immunotherapy in the metastatic and high-risk adjuvant setting has led to increasing interest in applying immune checkpoint blockade in the neoadjuvant setting for earlier-stage malignancies. With conventional chemo(radio)therapy, the neoadjuvant approach has been considered for patients with locally advanced disease for whom upfront surgery may not be feasible, with the goal of downstaging their disease to allow definite resection and improvement of local disease control. The neoadjuvant approach to conventional chemo(radio)therapy also has been shown to improve survival, surgical outcomes, or both for patients with bladder, 38 breast, [39] [40] [41] [42] [43] laryngeal, 44 esophageal [45] [46] [47] [48] [49] and rectal 50, 51 cancers. Additionally, efficacy of treatment can be evaluated preoperatively by monitoring tumor response and postoperatively by pathologic evaluation of the resected tumor tissue (Fig. 3 ). This allows a more tailored treatment because the therapy can be modified or changed for patients who did not respond to the neoadjuvant therapy.
The success of immune checkpoint therapy as treatment for advanced unresectable malignancies and in the adjuvant setting for patients with advanced high-risk stage 3 resected melanoma, as well as the precedent of the neoadjuvant approach to conventional chemotherapy has led to significant interest in exploring the potential role of neoadjuvant immune checkpoint blockade in a variety of malignancies (Table 1) . Although the clinical data to support the use of immune checkpoint blockade in the neoadjuvant setting currently are limited, more than 60 ongoing studies are exploring this strategy for several tumor types including melanoma, NSCLC, bladder cancer, RCC, ovarian cancer, prostate cancer, gastroesophageal cancer, colorectal cancer, mesothelioma, pancreatic cancer, breast cancer, and glioblastoma (Clinicaltrials.gov).
In the preclinical space, studies suggest that neoadjuvant immune checkpoint blockade may not only facilitate surgical resectability of high-risk or borderline resectable lesions but may also improve recurrence and survival outcomes compared with immune checkpoint blockade administered in the adjuvant setting. [52] [53] [54] In a recent study, Liu et al. 54 asked the highly relevant question using preclinical models of breast cancer: should immunotherapy be instituted before or after surgery? Using two transplantable models of breast cancer that spontaneously metastasize to the lungs, the authors tested three immunomodulatory monoclonal antibodies (mAbs) (anti-CD25 mAbs or other experimental strategies to deplete regulatory T cells, anti-PD-1 mAbs to block checkpoint activity, anti-CD137 to co-stimulate T cells) for their effect on overall survival when administered in the neoadjuvant versus adjuvant setting. Although the anti-PD-1 plus anti-CD137 mAbs combination was the most effective treatment, the survival benefit was better with all the treatments when administered before surgery. The authors demonstrated that neoadjuvant regimens engender more robust anti-tumor CD8? T cell responses than adjuvant regimens, which are required for therapeutic efficacy in these models.
Mechanistically, a neoadjuvant approach to immune checkpoint blockade seems to be favorable. 52 Before surgery, tumor-infiltrating lymphocytes, representing the majority of cells expressing targets for immune checkpoint inhibitors, are present where abundant tumor antigen is available for cross-priming at the time of immunotherapy.
Additionally, recirculation of T lymphocytes from the primary tumor infiltrate may address microscopic metastatic disease. These provocative preclinical studies clearly support the currently ongoing and future planned clinical trials to investigate and compare adjuvant, neoadjuvant, and combined neoadjuvant plus adjuvant immunotherapy regimens.
CURRENT APPROACHES USING NEOADJUVANT IMMUNE CHECKPOINT BLOCKADE

Clinical Trials of Neoadjuvant Immune Checkpoint Blockade in Melanoma 55
There is significant interest in examining the role of immune checkpoint blockade in the neoadjuvant setting for patients with resectable stage 3 and oligometastatic stage 4 melanoma. Investigators hypothesize that neoadjuvant immune checkpoint blockade may facilitate ease of surgical resection and possibly convert patients with borderline resectable stage 3 or 4 disease to resectable disease by the time of surgery. Additionally, there is interest in evaluating the impact of neoadjuvant checkpoint blockade on RFS and overall survival (OS) for these patients.
Currently, three phase 2 clinical trials are accruing that evaluate either anti-PD-1 antibody alone or in combination with anti-CTLA-4 antibody in the neoadjuvant setting for patients with stage 3 or 4 melanoma ( Table 1 ). The OpACIN-neo (NCT02977052) trial is an open-label, threearm phase 2 study evaluating 90 stage 3 melanoma patients randomized 1:1:1 to receive two courses of ipilimumab 3 mg/kg ? nivolumab 1 mg/kg every 3 weeks, two courses of ipilimumab 1 mg/kg ? nivolumab 3 mg/kg every 3 weeks, or two courses of ipilimumab 3 mg/kg directly followed by 2 courses of nivolumab 3 mg/kg every 2 weeks. The patients in all three treatment arms then undergo surgery. The primary outcome measures include response rate by RECIST1.1, safety, and pathologic response. The secondary outcome measures include RFS, late adverse events, and correlatives.
The NCT02519322 trial is a phase 2 study accruing patients with high-risk resectable stage 3 and oligometa- This is a single-center cross-sectional imaging and correlative biomarker study of patients with HNSCC. Cohort 1 will be patients with unresectable or metastatic HNSCC receiving standard-of-care anti-PD-1 treatment, and cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1 treatment before tumor resection or radiation.
NCT03003637
Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to surgery in advanced or recurrent HNSCC (IMCISION) 1/2 Not yet recruiting (32) This trial will examine the feasibility and safety of neoadjuvant checkpoint blockade to standard-of-care surgery in advanced-stage HNSCC.
NCT02812524
Ipilimumab for head and neck cancer patients 1 Recruiting
This study examining patients with squamous cell carcinoma of the head and neck tests the feasibility of administering intratumoral injections of ipilimumab before surgical resection and the immune system response to treatment.
NCT03021993
Trial of nivolumab as a novel neoadjuvant presurgical therapy for locally advanced oral cavity cancer
2 Not yet open (19) This study will examine the effectiveness of nivolumab in patients with oral cavity cancer who are about to undergo surgery. This is a pilot study on the side effects of nivolumab and how well it works in treating patients with high-risk kidney cancer that has not spread to other places in the body.
NCT02812420
Presurgical study evaluating anti-PD-L1 antibody (durvalumab) plus anti-CTLA-4 (tremelimumab) in patients with muscleinvasive, high-risk urothelial carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy 1 Recruiting (15) This clinical research study aims to learn whether the combination of durvalumab and tremelimumab is safe and tolerable when given to patients with bladder cancer before surgery to remove the bladder.
NCT02845323
Neoadjuvant nivolumab with and without urelumab in patients with cisplatin-ineligible muscle-invasive urothelial carcinoma of the bladder
2 Not yet open (44) This study evaluates the post-cystectomy CD8? tumor response of patients receiving nivolumab ? urelumab vs nivolumab alone.
Breast carcinoma NCT02957968 Neoadjuvant pembrolizumab ? decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-negative breast cancer 2 Recruiting (50) This study is a 2-cohort, open-label, multicenter study of a short course of immunotherapy consisting of sequential decitabine followed by pembrolizumab administered before a standard neoadjuvant chemotherapy regimen for patients with locally advanced HER2-negative breast cancer. This open-label, multicentric, international trial tests aromatase inhibitors in combination with durvalumab in patients with CD8? T cell infiltration ([ 10% CD8? T cells in the tumor). The trial includes two sequences. The first part of the treatment will consist in 4-6 weeks treatment with immune-attractants. In the second part, CD8? patients will receive 6 months of durvalumab combined with exemestane.
NCT02833233
A study of preoperative treatment with cryoablation and immune therapy in earlystage breast cancer 1 Recruiting
This study evaluates the safety of combining two strategies called ''cryoablation'' and ''immune therapy'' in women with curable early-stage breast cancer.
Gastroesophageal cancers NCT02735239 Study of anti-PD-L1 in combination with chemo(radio)therapy for esophageal cancer
This open-label study will evaluate the safety of durvalumab (MEDI4736) combined with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced esophageal cancer (OC) and with neoadjuvant chemo(radio)therapy before surgery in operable OC. Immunotherapy will be given for a 4 week period before start of the standard chemo(radio)therapy, with durvalumab treatment continued once the chemotherapy starts.
NCT02918162
Perioperative chemo and pembrolizumab in gastric cancer 2 Recruiting
This study aims to determine and evaluate the efficacy of combination therapy with immune checkpoint blockade and chemotherapy used during the perioperative period in eradicating micrometastatic disease, and to compare paired tissue and serum samples (pre-and posttreatment) from individually treated patients to explore the immune effects of combination therapy and predictors of response. This study hypothesizes is that anti-PD-1 (nivolumab) or anti-PD-1/CTLA-4 (ipilimumab) administration in the preoperative setting and nivolumab combined with chemoradiation will be safe and feasible for patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristics of the tumor microenvironment, improving survival. This clinical research study aims to learn whether tremelimumab in combination with MEDI4736 can help to control colorectal cancer that has spread to the liver. The safety of these drugs will also be studied. NCT03026140
Nivolumab, ipilimumab and COS2-inhibition in early-stage colon cancer: an uniased approach for signals of sensitivity (NICHE) 2 Recruiting (60)
Patients with stages 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy ? COX2 inhibitors. This treatment will be given during the window period (* 6 weeks) until surgical resection of the tumor.
NCT02948348
Study of nivolumab after preoperative chemoradiotherapy
This open-label, single-arm, multicenter study investigates the safety, efficacy, and proof of concept of monotherapy with nivolumab as a sequential therapy after chemoradiotherapy with capecitabine and subsequent surgical therapy for patients with locally advanced resectable rectal cancer.
NCT03127007
Safety and efficacy of atezolizumab combined with preoperative radiochemotherapy in localized rectal cancer (R-IMMUNE) 1/2 Not yet recruiting (54) This study aims to determine the safety and tolerance of administration at a fixed dosing of 1200 mg/3 weeks, concomitantly to the standard preoperative radiochemotherapy and to explore the efficacy of atezolizumab in combination with the standard preoperative chemo/radiotherapy in stages 2 and 3 rectal cancers.
static stage 4 melanoma to receive either nivolumab alone (3 mg/kg every 2 weeks) or in combination with ipilimumab (nivolumab 1 mg/kg with ipilimumab 3 mg/kg every 3 weeks) before surgery (Fig. 4) . Adjuvant nivolumab (3 mg/kg every 2 months) will be administered postoperatively for 6 months. The primary outcome measure is the pathologic response by evaluation of the resected melanoma specimen. The secondary outcome measure is immunologic response to therapy as determined by change in T cell infiltrate from baseline to on-treatment and surgical specimens. The NeoPembroMel (NCT02306850) trial is a phase 2 study that differs from the former two trials in that it is enrolling patients with unresectable stage 3 or 4 melanoma to determine whether treatment with pembrolizumab can convert or shrink unresectable disease to resectable tumors. The primary outcome is the resectability rate, defined as the proportion of patients in the trial who were unresectable at baseline but became eligible for curative resection with complete metastectomy after treatment with pembrolizumab (200 mg every 3 weeks for at least 24 weeks and up to 2 years).
Two additional trials of neoadjuvant combination therapy, one with pembrolizumab and high-dose IFN-alfa2b (NCT02339324) and one with ipilimumab and high-dose IFN-alfa2b (NCT01608594), are not recruiting participants but are ongoing. In these trials, patients receive adjuvant IFN-alfa2b after recovery from surgery every other day three times weekly for 46 additional weeks. The primary outcome measure of these two phase 1 trials is the safety of these combinations, and the secondary outcome is the pathologic and radiologic response rates, progression-free survival, and OS.
Clinical Trials of Neoadjuvant Immune Checkpoint Blockade in Other Solid Malignancies
As with melanoma, much excitement exists regarding the potential use of immune checkpoint blockade in the neoadjuvant setting across solid tumor types including NSCLC, head/neck squamous cell carcinoma (HNSCC), urothelial carcinoma and RCC, breast cancer, gastroesophageal cancer, colorectal cancer, pancreatic adenocarcinoma, and soft tissue sarcoma, with more than 60 ongoing clinical trials (Table 1) . These are predominantly phase 1 or 2 studies investigating the safety and feasibility of preoperative administration of anti-CTLA-4 and/or anti-PD-1 antibody therapies, either as single agents or in combination, with patients receiving additional adjuvant immune checkpoint therapy postoperatively in some studies. Additionally, some phase 2 studies of certain disease sites (NSCLC, breast, gastroesophageal, and pancreatic) aim to evaluate the safety and feasibility of combining neoadjuvant immune checkpoint blockade with conventional chemo(radio)therapies and endocrine therapies. The NCT02812524 trial is a phase 1 study testing the feasibility of intratumor ipilimumab injections before surgical resection for patients with HNSCC. The outcome measures of interest in these studies include the clinical objective response rate, the pathologic response, and the efficacy of neoadjuvant immune checkpoint blockade in facilitating surgical resection, as well as the impact on RFS, distant RFS, and OS.
Currently, one phase 3 study is recruiting 766 patients with non-metastatic stage 2 or greater RCC, randomized to either surgical resection followed by observation or neoadjuvant nivolumab (q2wks 9 2 doses) followed by resection and adjuvant nivolumb (q2wks for 6 doses followed by qmonth 9 6 doses) (PROSPER RCC, NSCLC non-small cell lung cancer, PD-L1 programmed death ligand 1, HNSCC head and neck squamous cell carcinoma, RCC renal cell carcinoma, CTLA-4 cytotoxic T lymphocyte-associated antigen 4, HER2 human epidermal growth factor receptor 2 NCT03055013). The primary outcome measure is RFS, and the secondary outcome measures include OS and the incidence of adverse events.
CAVEATS AND FUTURE DIRECTIONS
Second, although the main outcomes for many studies of neoadjuvant immune checkpoint blockade are the response rate and the pathologic response rate, it remains to be seen whether the response rate will truly predict a long-term survival benefit conferred by immune checkpoint inhibitors when administered in the neoadjuvant setting.
Despite the tremendous success of immune checkpoint blockade in advanced malignancies and the marked excitement about the expanding role of these novel therapies to include earlier-stage disease and in the neoadjuvant setting, a number of questions remain where data are currently lacking. First, there is concern that pursuing a neoadjuvant approach to immune checkpoint therapy may result in patients losing the opportunity for surgical resection (becoming unresectable with disease progression in nonresponders). Thus, current and future research investigating predictors of response and resistance to immune checkpoint blockade is of utmost importance and relevance. 56 This is also of importance because immunotherapies are not benign and are associated with immune-related adverse drug reactions including colitis, hepatitis, pneumonitis, and endocrinopathies. 57 This is an exciting time in clinical oncology as we are embarking upon an era of novel immunotherapies, including immune checkpoint blockade. Whereas the PD-1/PD-L1 axis and CTLA-4 govern the most prominent immune pathways targeted currently, antibodies targeting other inhibitor receptors (e.g., LAG-3) and activating immune receptors (e.g., CD27 and OX40) are being developed and investigated in preclinical and clinical studies. The potential of these new therapies in the neoadjuvant setting are unknown. As we begin to elucidate the role of immune checkpoint blockade in earlier-stage malignancies and in the neoadjuvant setting, another set of unanswered questions involves the interplay between immunotherapy and current standard treatment regimens (radiation, conventional chemotherapy) and whether neoadjuvant immunotherapy in combination with these may provide synergistic benefit. DISCLOSURES Jennifer A. Wargo is a co-founder and scientific advisor to Microbiome DX, received clinical trial support from Roche-Genentech, GSK, BMS, and Novartis; is an advisory board member for Roche-Genentech, GSK, and Novartis; and is on the speaker's bureau for Imedex, Dava, Omniprex, and Illumina. 
